Researchers have shown that the investigational drug triphendiol causes cell death in pancreatic and bile duct cancer cell lines, slows tumor growth and sensitizes tumors to chemotherapy treatments. Scientists assessed the potential of triphendiol as a treatment for pancreatic adenocarcinoma using three representative cell lines.